Skip to content
MARKETS / BALCAO / YBGJ
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Yubo International Biotech Ltd. YBGJ

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$12,353
▲ 256.0% YoY
$-1.1M
In brief

What this company does

Yubo Beijing offers its products and services under the brand “VIVCELL.” Yubo Beijing’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. Yubo Beijing also offers stem cell related services including cell testing and health management consulting services.

Written from the business description in Yubo International Biotech Limited's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 12,353.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.1
0.5M1.0M-0.8M-1.6M201020122014201620182020202220242025
Compound annual growth
−50.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−9617 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -9614.6% · Net -9616.6%
-20000%-40000%201020122014201620182020202220242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -0.6
-0.8M201020122014201620182020202220242025

Total assetsUSD 847,094.00
EquityUSD -2.0M
CashUSD 8,062.00
DepositsUSD 71,135.00
Current ratio0.24×

Equity funds -231% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.0·0.00.00.00.00.00.00.0·0.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0··········
Income tax $B0.00.00.00.00.00.00.00.00.00.00.0·····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B···−0.0−0.00.0··········
EPS, diluted $−0.01−0.02−0.10···−0.11−0.13−0.12−0.19−0.11−0.10−0.09−0.09−0.07−0.09
Dividend / sh $················
Payout %················
ROE %····−297.6···········

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 46 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inNew York
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image